Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

VALERIO, Maria Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.931
EU - Europa 4.492
AS - Asia 3.759
SA - Sud America 797
AF - Africa 88
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 17.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.807
SG - Singapore 1.511
CN - Cina 1.119
IT - Italia 901
RU - Federazione Russa 721
DE - Germania 672
BR - Brasile 641
FI - Finlandia 584
UA - Ucraina 423
HK - Hong Kong 375
PL - Polonia 324
VN - Vietnam 292
GB - Regno Unito 238
IE - Irlanda 174
SE - Svezia 138
IN - India 89
KR - Corea 70
AR - Argentina 69
FR - Francia 66
CA - Canada 55
BE - Belgio 45
MX - Messico 42
TR - Turchia 41
AT - Austria 40
NL - Olanda 36
JP - Giappone 35
BD - Bangladesh 32
IQ - Iraq 31
ES - Italia 28
RO - Romania 26
IR - Iran 22
UZ - Uzbekistan 22
EC - Ecuador 20
ZA - Sudafrica 18
GR - Grecia 17
VE - Venezuela 17
PK - Pakistan 15
ID - Indonesia 14
CI - Costa d'Avorio 13
CO - Colombia 13
MA - Marocco 13
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
MY - Malesia 11
CH - Svizzera 10
KE - Kenya 10
SA - Arabia Saudita 9
TN - Tunisia 9
DZ - Algeria 8
EG - Egitto 8
KZ - Kazakistan 8
LT - Lituania 8
PE - Perù 8
AL - Albania 7
HN - Honduras 7
PH - Filippine 7
RS - Serbia 7
CL - Cile 6
JM - Giamaica 6
JO - Giordania 6
LB - Libano 6
NP - Nepal 6
IL - Israele 5
UY - Uruguay 5
BG - Bulgaria 4
BO - Bolivia 4
BY - Bielorussia 4
EU - Europa 4
GE - Georgia 4
NO - Norvegia 4
AU - Australia 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
MN - Mongolia 2
NG - Nigeria 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AO - Angola 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BZ - Belize 1
CY - Cipro 1
DM - Dominica 1
FK - Isole Falkland (Malvinas) 1
GD - Grenada 1
GF - Guiana Francese 1
GT - Guatemala 1
HU - Ungheria 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
Totale 17.062
Salva come PNG Salva come JPEG
Città #
Ashburn 948
Singapore 934
Fairfield 860
Chandler 538
Woodbridge 488
Wilmington 443
Hong Kong 364
Houston 364
Ann Arbor 360
Seattle 340
Zgierz 293
Cambridge 281
Moscow 262
Jacksonville 229
Beijing 190
Dublin 174
Medford 168
Hefei 138
Des Moines 130
San Jose 126
Palermo 119
Dallas 116
Los Angeles 111
Ho Chi Minh City 109
New York 109
Princeton 107
Altamura 104
Santa Clara 104
Nanjing 98
The Dalles 95
Lawrence 79
Boardman 70
São Paulo 68
Buffalo 67
Hanoi 62
San Diego 59
Tulsa 58
Dearborn 55
Milan 55
Ludwigshafen am Rhein 53
Rome 50
Helsinki 49
London 47
Brussels 45
Chicago 41
Nuremberg 40
Shenyang 39
Tianjin 38
Jinan 36
Hebei 35
Seongnam 33
Munich 32
Frankfurt am Main 31
Seoul 30
Tokyo 28
Council Bluffs 27
Nanchang 27
Falls Church 26
Rio de Janeiro 25
Changsha 23
Columbus 23
Lappeenranta 23
Stockholm 23
Guangzhou 22
Jiaxing 21
Montreal 21
Poplar 21
Brooklyn 20
Denver 20
Kerken 20
Venice 20
Vienna 20
Warsaw 19
Berlin 18
Zhengzhou 18
Kumar 17
Ningbo 17
Saint Petersburg 17
Curitiba 16
Phoenix 16
Redondo Beach 16
Tashkent 16
Ankara 15
Boston 15
Washington 15
Atlanta 14
Hangzhou 14
Redwood City 14
Abidjan 13
Baghdad 13
Brasília 13
Haiphong 13
Izmir 13
Orem 13
San Francisco 13
San Mateo 13
Chennai 12
Kitzingen 12
San Paolo di Civitate 12
Tehran 12
Totale 10.693
Salva come PNG Salva come JPEG
Nome #
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 289
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 263
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 263
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 253
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 234
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 232
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor 232
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma 228
A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers 228
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 228
Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy 225
Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 224
Clinical presentation and treatment of gastrointestinal stromal tumors. 221
Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents 219
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. 211
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale 200
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 198
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 196
L'impiego del Tachosil in chirurgia epatica 188
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 187
Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes 186
Alexithymia and coping style in women going to visit in a breast cancer center. 183
Mutational analysis of BRCA1 gene in sicilian patients at risk for inherited breast and/or ovarian cancer: experience of reference centre for the biomolecular characterization of neoplasms and genetic screening of hereditary tumors. 177
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). 177
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 176
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 175
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 170
Analysis of Ki-ras mutations in stage I rectal carcinomas and respective regional lymphonodes 169
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 166
Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: report of a case. 166
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. 165
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. 164
A.Mutational analysis of BRCA1 in sicilian patients at risk for inherited of reference center for the biomolecular characterizaztion of neoplasm and genetic screening of hereditary tumors 163
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial 162
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study 161
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 159
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes 159
A Case of Follicular Tumor of Uncertain Malignant Potential (FT-UMP) with Glomeruloid Features Showing Capsular Mucinous Degeneration 159
Gastric metastasis from breast cancer 158
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome 156
Detection of free-circulating tumor DNA in plasma of patients with gastrointestinal cancer. 149
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 148
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation 148
Mutational analysis of BRCA1 gene in sicilian patient at risk for inherited breast and/or ovarian cancer: experience of reference center the biomolecular characterization of neoplasm and genetic screening of hereditary tumors. 147
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer 146
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. 146
Evaluation of predictive factors for i-CLARAS (intraoperative complications in laparoscopic renal and adrenal surgery): a multicentre international retrospective cohort study 145
Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer 145
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study 143
Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study 141
The prognostic role of TP53 mutations in advanced laryngeal squamous cell carcinoma (LSCC). 140
Alexithymia and copyng style in women going to visit in a breast cancer center 137
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 137
TP53 mutations are not prognostic independent indicators in bladder cancer. 135
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience 135
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study 135
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 134
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 130
Cardiotossicità e Cardioprotezione. 130
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study 130
TP53 mutations and S-Phase fraction are independent prognostic indicators in locally advanced laryngeal squamous cell carcinoma 129
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 128
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 127
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 126
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis 126
Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato. 125
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 123
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 122
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 122
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 121
The Use of Gemcitabine in heavily pretreted breast cancer patients 120
Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma 119
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? 119
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel 117
RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI 113
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study 110
GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY 110
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 110
TP53 Mutation in exon 5 and S-Phase Fraction but not Mutations in Ras gene family and DNA-ploidy are Indipendent prognostic indicators in Laryngeal Squamous Cell Carcinoma 109
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up 109
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 108
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient 106
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience 104
Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer 103
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma 101
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World 100
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 98
TP53 mutations are not prognostic indipendent indicators in bladder cancer 97
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 96
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 94
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data 94
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: The G-Step trial 93
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 93
A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer 91
Relationship between the thymidylate synthase, p53 levels with the treatment by Cyclophosphamide, Metotrexate, 5-Fluorouracil chemotherapy (CMF) versus Docetaxel (TXT) in the locally advanced carcinoma of breast. 91
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs) 88
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 87
STUDIO DI FASE II: DOCETAXEL SETTIMANALE COME SECONDA LINEA CHEMIOTERAPICA NEL CARCINOMA PROSTATICO AVANZATO 86
Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy 83
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review 82
Totale 14.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021923 0 0 0 0 0 0 186 92 156 165 158 166
2021/20221.307 81 252 26 76 69 48 84 67 147 156 81 220
2022/20231.607 166 310 29 155 189 243 105 110 164 8 72 56
2023/2024987 41 127 80 72 62 138 181 55 25 19 58 129
2024/20252.704 71 198 249 205 119 80 191 189 188 312 293 609
2025/20264.997 677 416 632 731 980 1.284 277 0 0 0 0 0
Totale 17.746